Joseph Caprini to Cost-Benefit Analysis
This is a "connection" page, showing publications Joseph Caprini has written about Cost-Benefit Analysis.
Connection Strength
0.107
-
The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Int Angiol. 2002 Mar; 21(1):78-85.
Score: 0.041
-
Cost-effective laparoscopic cholangiography. Surg Laparosc Endosc. 1994 Apr; 4(2):142-5.
Score: 0.024
-
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260.
Score: 0.022
-
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002 Nov; 24(11):1960-86; discussion 1938.
Score: 0.011
-
The use of a Bayesian forecasting model in the management of warfarin therapy after total hip arthroplasty. J Arthroplasty. 1999 Dec; 14(8):988-93.
Score: 0.009